Marcellus’ Consistent Compounders Portfolio consists of companies which have already delivered consistently healthy growth in their fundamentals over the past decade or longer, and where we expect the firms to deliver consistent compounding over the next decade as well. However, given the long and consistent historical track record of these companies, some investors are concerned around saturation of the growth runway for these firms given their large size vs global players in similar categories and given their already dominant market shares. Our portfolio companies overcome these potential challenges by: a) orienting their product portfolio towards a high volume of small ticket day-to-day essentials in a country which offers a long run-way for growth in middle class household consumption; and b) executing business expansion through institutionalised systems and processes, minimising product price hikes, and successfully expanding their product portfolio over time in adjacent product categories.

 

Performance update – as on 30th November 2019

 

We have a coverage universe of around 25 stocks, which have historically delivered a high degree of consistency in ROCE and revenue growth rates. Our research team of five analysts focuses on understanding the reasons why companies in our coverage universe have consistently delivered superior financial performance. Based on this understanding, we construct a concentrated portfolio of companies with an intended average holding period of stocks of 8-10 years or longer. The latest performance of our PMS and offshore fund (USD denominated) portfolios is shown in the charts below.

Common apprehensions around size of consistent compounders

One of the first steps we take in our research process while trying to identify a ‘Consistent Compounder’ is a 10-years or longer historical track record of consistent and healthy fundamentals. In fact, many firms in our holding portfolio and in our coverage universe have delivered more than 20 years of consistency of healthy fundamentals. Such long and consistent track record of healthy fundamentals clearly means that by now most of our portfolio companies have become large in size (in terms of revenues, volumes, market share, etc).

Moreover, given the low intended churn in our portfolio, our average holding period of a stock in the portfolio is likely to be at least 8-10 years. This means that at the very least, we don’t expect our portfolio companies to face saturation in terms of the growth run-way available to them.

However, some of the common apprehensions that an investor might come across while investing in Consistent Compounders are:

Another way of looking at the growth runway

Let’s consider the following points about the three companies mentioned above – Relaxo, HDFC Bank and Bajaj Finance:

 

What prevents consistent compounders from saturating in their growth potential?

The context given in this newsletter so far suggests that companies which have become 100 times (or more) bigger in size over the past two decades are not necessarily approaching saturation in their growth rates. This happens because of the following factors:

    1. Demographic dividend: A young and large population combined with economic growth supported by rising middle class household consumption provides a long runway for growth to most sectors in India. To draw a parallel – it is true that America’s largest bank JP Morgan Chase is only 7x bigger than HDFC Bank, and only thrice as big as State Bank of India in terms of its loan book size. However, it is also true that China has four state owned banks – ICBC, China Construction Bank Corp, Agriculture Bank of China, and Bank of China – each of these is twice as big as JP Morgan.
    2. Ability to successfully expand into adjacencies over time: Page Industries started its business in India with only mens innerwear 25 years ago – a category which is ~Rs 10,000 crores in category size currently. However, today under the same brand Jockey, Page has successfully expanded into women’s innerwear, leisurewear (outerwear), and kidswear – a total category size of over Rs 40,000 crores currently. In footwear, 20-25 years ago, Relaxo Footwears used to sell predominantly rubber hawai chappals (white flip flops with blue straps) under the brand of Relaxo. Today, the firm has diversified into sports shoes (Sparx), floaters (Sparx), premium flip flops (Flite, Bahamas) etc. While Bajaj Finance was focused predominantly on consumer durable loans 8-10 years ago, today consumer durable loans contribute to no more than 10% of its overall loan book with the balance being diversified across home loans, business loans, personal loans etc. This ability to keep widening the basket of products whilst also sustaining the firm’s competitive advantages helps avoid market share related stagnation within a single product category.
    3. Institutionalised systems and processes help play the small-ticket, high-volume game: A combination of large population in India and significant under-penetration of economy products in some of the most basic categories of day-to-day essentials creates a huge opportunity for a firm to scale up volumes in product categories of low ticket sizes. However, scaling up a pan-India business in such small ticket categories becomes difficult given the heterogeneity of consumer tastes and preferences across geographies, religions, socio-economic stratas; poor transportation and logistics infrastructure; demand centers which are remotely located from each other; and several local unorganized competitors as incumbents. One of the most common solutions to these challenges implemented by consistent compounders has been a strong focus on institutionalizing: a) IT investments in distribution and sales; b) professional empowerment of high quality talent; and c) strategic decision-making through an empowered and independent board of directors.
    4. A focus on product affordability via minimum price hikes: With price elasticity of demand being particularly high in low-ticket size product categories of day-to-day essentials, most Consistent Compounders minimise product price hikes while focusing on operating efficiencies to protect their profitability over time. This, combined with various other competitive advantages of these firms, ensures that there is limited room for a competitor to significantly disrupt the consistent compounder by way of ‘price wars’ by undercutting product prices. For instance, over the last couple of decades, Asian Paints has hiked product prices on a like for like basis by around 2.5% CAGR. Similarly, over the past 3-4 years, Dr. Lal Pathlabs has not hiked prices for its diagnostics tests at all.

 

Investment implications

Most stocks in our Consistent Compounders portfolio exhibit the characteristics mentioned above while executing their business expansion. Provided, we continue to have conviction on the ability of our portfolio companies to sustain their competitive advantages, the risk of the growth runway becoming saturated appears to us to be low. Our analysis shows that the growth runway available to most of our portfolio companies – from category growth or market share gains or ability to expand the basket of product portfolio – remains long.

Regards

Team Marcellus

If you want to read our other published material, please visit https://marcellus.in/

Note: the above material is neither investment research, nor investment advice. Marcellus does not seek payment for or business from this email in any shape or form. Marcellus Investment Managers is regulated by the Securities and Exchange Board of India as a provider of Portfolio Management Services and as an Investment Advisor.

 

Copyright © 2019 Marcellus Investment Managers Pvt Ltd, All rights reserved.